Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIM PASC platform trial of minocycline
NL-OMON60183Phase 3Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of minocycline in post-COVID syndrome (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: PROMIS-29 physical health summary score. Started Feb 2025; status: recruiting.
02
Drugs
minocycline
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on NL-OMON60183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60183.